Aktis Oncology
aktisoncology.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Aktis Oncology to Present at Upcoming September Investor Conferences
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (
Read more
Report
Aktis Oncology to Present at Upcoming September Investor Conferences
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (
Read more
Report
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
--Aktis Oncology, Inc., a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial resu
Read more
Report
Aktis Oncology Inc. (AKTS) - Insider Monkey
Aktis Oncology Inc. (AKTS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey.
Read more
Report
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
What recent performance says about Aktis Oncology Aktis Oncology (AKTS) has drawn fresh attention after recent trading, with the stock up 6.4% on the day and 9.3% over the past week, even as it is down 4.3% over the past month. See our latest analysis for
Read more
Report
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33
Aktis Oncology, Inc. (NASDAQ:AKTS) is one of the 8 Healthcare Stocks Insiders Are Buying. On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm's price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintaine
Read more
Report
Aktis Oncology: $175 Million (Series B) Secured To Develop Targeted Alpha Radiopharmaceuticals For Treating Tumors
Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the successful closing of an oversubscribed and upsized $175 mil
Read more
Report
People
Shulamit Ron-Bigger
Executive Officer
Matthew Roden
Executive Officer, Director
Helen Kim
Director
Ken Herrmann
Director
Lloyd Segal
Director
Oleg Nodelman
Director
Andrew Levin
Director
Todd Foley
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Boston
United States
HQ
BOSTON, MA
17 Drydock Avenue, Suite #17-401Boston, MA 02210
Park
United States
Engineering / R&D
RESEARCH TRIANGLE PARK, NC
801 Capitola Drive, Building 1Durham, NC 27713
Financials
Total raised
$175M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $175M | Details |